Lainiola Mira, Linden Anni-Maija
Department of Pharmacology, Faculty of Medicine, University of Helsinki, Finland.
Department of Pharmacology, Faculty of Medicine, University of Helsinki, Finland.
Alcohol. 2017 Dec;65:1-10. doi: 10.1016/j.alcohol.2017.06.002. Epub 2017 Sep 14.
Neuroinflammation may play an important role in the development of alcohol addiction. Recent preclinical reports suggest that enhanced innate immune system signaling increases consumption of alcohol. Our aim was to study whether consequences of lipopolysaccharide (LPS)-induced sickness reaction increase long-term alcohol intake. Adult male C57BL/6J mice, housed in individually ventilated cages, were injected with LPS intraperitoneally (i.p.) and allowed to recover from an acute sickness reaction for 1 week before analysis of their alcohol intake in two different drinking models. Effects of LPS challenge were tested in a continuous two-bottle free choice test with increasing concentrations of alcohol and in a drinking in the dark (DID) binge model. In addition, the effect of repeatedly administered LPS during abstinence periods between binge drinking was analyzed in the DID model. In addition, the DID model was used to study the effects of the microglia inhibitor minocycline (50 mg/kg/day, 4 days) and purinergic P2X7 receptor antagonist Brilliant Blue G (75 mg/kg/day, 7 days) on alcohol intake. In contrast to previous findings, pretreatment with a 1-mg/kg dose of LPS did not significantly increase ethanol consumption in the continuous two-bottle choice test. As a novel finding, we report that increasing the LPS dose to 1.5 mg/kg reduced consumption of 18 and 21% (v/v) ethanol. In the DID model, pretreatment with LPS (0.2-1.5 mg/kg) did not significantly alter 15% or 20% ethanol consumption. Neither did repeated LPS injections affect binge alcohol drinking. Minocycline reduced alcohol, but also water, intake regardless of LPS pretreatment. No data on effects of P2X7 antagonists on alcohol consumption have been previously published; therefore, we report here that subchronic Brilliant Blue G had no effect on alcohol intake in the DID model. As a conclusion, further studies are needed to validate this LPS model of the interaction between immune system activation and alcohol consumption.
神经炎症可能在酒精成瘾的发展中起重要作用。最近的临床前报告表明,先天性免疫系统信号增强会增加酒精的摄入量。我们的目的是研究脂多糖(LPS)诱导的疾病反应的后果是否会增加长期酒精摄入量。将成年雄性C57BL/6J小鼠饲养在独立通风的笼子中,腹腔内注射LPS(i.p.),并在急性疾病反应恢复1周后,在两种不同的饮酒模型中分析它们的酒精摄入量。在连续两瓶自由选择试验中,用浓度递增的酒精测试LPS激发的效果,并在黑暗中饮酒(DID)暴饮模型中进行测试。此外,在DID模型中分析了在暴饮之间的禁欲期重复给予LPS的效果。此外,DID模型用于研究小胶质细胞抑制剂米诺环素(50mg/kg/天,4天)和嘌呤能P2X7受体拮抗剂亮蓝G(75mg/kg/天,7天)对酒精摄入量的影响。与先前的研究结果相反,在连续两瓶选择试验中,1mg/kg剂量的LPS预处理并没有显著增加乙醇消耗量。作为一项新发现,我们报告将LPS剂量增加到1.5mg/kg可使18%和21%(v/v)乙醇的消耗量减少。在DID模型中,LPS(0.2-1.5mg/kg)预处理并没有显著改变15%或20%乙醇的消耗量。重复注射LPS也不会影响暴饮酒精。无论LPS预处理如何,米诺环素都会减少酒精摄入量,但也会减少水的摄入量。以前没有关于P2X7拮抗剂对酒精消耗影响的数据发表;因此,我们在此报告,亚慢性亮蓝G对DID模型中的酒精摄入量没有影响。总之,需要进一步研究来验证这种免疫系统激活与酒精消耗之间相互作用的LPS模型。